The FDA approved a molecularly targeted therapeutic for treating certain patients with some rare cancers affecting the gastrointestinal system. The U.S. Food and...
African American men are more likely to feel regret about prostate cancer treatment decisions, and more news of the...
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form...
People are using crowdsourced fundraising to cover cancer care costs, and more news of the week from Cancer Today.
Guest Post by William G. Nelson, MD, PhDEditor-in-Chief, Cancer Today Clearly, cancers that have metastasized, or spread, to many different...
Researchers in Japan observe the rare occurrence of a mother passing cancer cells to their child, and more news...
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer....
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a...
In the early 1970s, German virologist Harald zur Hausen, MD, FAACR, defied the dogma that cervical cancer was caused by the herpes simplex...
As the year draws to a close, we bring you the final edition of Editors’ Picks for 2020. This monthly roundup features one “must read” article, handpicked by...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 47,000 members worldwide drive progress against cancer.
Donate Now